entertainment -WSS

entertainment

author：Wikipedia 2025-10-01 09:00:20 - browse：7947

Fiona Marshall, president of the Novartis research hub in Cambridge, Mass., speaks Thursday during the STAT Future Summit. STAT

Swiss drugmaker Novartis’ research and development hub has a new name — and a new guiding strategy.

The hub, which is headquartered in Cambridge, Mass., and for years has been known as Novartis Institutes for BioMedical Research, or NIBR, will soon simply be known as Novartis Biomedical Research.

But that’s not the only thing that’s changing, Fiona Marshall, the hub’s president, told a virtual audience Thursday during the 2023 STAT Future Summit. The new name reflects a larger shift by the pharma giant to retool its research strategy — from one driven by the pure pursuit of scientific discovery to a tighter focus on projects likely to yield commercially successful drugs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Venture capitalist Bob Kocher on the state of digital health

WSS

When prostate cancer spreads, where it goes matters

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Children’s Hospital revives plan for pedestrian bridge

Children’s Hospital revives plan for pedestrian bridge

Anxious about a speech? A startup wants you to pop a minty cardiac drug

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

hotspot

entertainment

hotspot

Cancer drug shortages should be causing more outrage

Laying a path for careers in science

Cancer drug shortages should be causing more outrage

CDC panel: People 65 and older should get a Covid spring booster shot

In Memoriam: Notable people who died in 2023

NVIDIA and Google execs on the future of AI and drug discovery

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Arc Institute generative AI designs new CRISPR systems

focus

Children’s Hospital revives plan for pedestrian bridge

'Vaccine

Medicare Advantage isn’t working — for anyone

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Pfizer is about to make a big push in cancer. Will investors listen?

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

focus

entertainment

Wikipedia

focus